The Stage Is Set: London Biotechnology Show 2025
The inaugural London Biotechnology Show (LBS 2024) took place on 8–9 May 2024 at Olympia West, London, and culminated in an insightful discussion of emerging disruptive technologies such as AI in drug discovery, scalable cell and gene therapies and many more, ultimately attracting over 3,000 attendees and 1,500 companies across the biopharma sector.
Building on its successful debut last year, London Biotechnology Show returns on 18–19 June 2025 at ExCeL London (Halls N7 & N8). Organisers project over 3,500 business attendees with representation from 1,800 biotech companies, 110 exhibitors, and 100 speakers. The two-day format will combine a multi-track conference, addressing advancements in the field of cell and gene therapies, AI-driven bioprocessing, precision medicine, and regulatory frameworks, with an extensive exhibition, a startup showcase and a hosted buyer programme to foster strategic partnerships between pre-qualified buyers and exhibitors.
Networking zones, roundtables, and evening receptions will further encourage collaborations across academia, industry, and government. To navigate between concurrent sessions and streamline your conference experience, please see LBS 2025 agenda.
The conference is going to feature a world-class lineup of speakers including:
- Howard Dawber - Deputy Mayor of London for Business and Growth, who will highlight the city’s strategic initiatives to support biotech innovation.
- Professor Chris Johnson - Chief Scientific Advisor Department for Science, Innovation and Technology, overseeing national research priorities in life sciences.
- Claire Kerridge - Regulatory Affairs Lead MHRA, responsible for shaping UK regulations on cell and gene therapies.
- Professor Sir Mark Caulfield - Vice Principal for Health Queen Mary University of London, a geneticist renowned for leading large-scale population genomics studies.
- Robert Vries - CEO HUB Organoids Merck, leading efforts to commercialize human organoid platforms for drug discovery.
- Dr Nicole Mather - Health & Life Sciences Leader IBM, specializing in AI-driven analytics for healthcare applications.
- Thomas Balkizas - Senior Director Life Sciences Microsoft, architecting cloud-based AI platforms for genomics and proteomics.
- Jakob E. Larsen - Target Discovery Project Director, Novo Nordisk, leading precision-medicine research in metabolic and renal diseases.
In turn, the exhibition this year hosts established industry leaders, including:
- Thermo Fisher Scientific, a global powerhouse in laboratory equipment, reagents, and services.
- Merck, a global life science leader providing a broad portfolio of research tools, reagents, and digital platforms to accelerate drug discovery, biomanufacturing, and diagnostics.
- Agilent Technologies, renowned for its solutions in genomics, proteomics, metabolomics, and chemical analysis through the provision of analytical instruments and software.
- Haier Biomedical UK Ltd, a global leader in biomedical refrigeration and cold chain solutions which provide advanced storage technologies for samples, vaccines, and pharmaceuticals.
- ProteoGenix, a leading provider of antibody production, protein expression, and gene synthesis services, is accelerating drug discovery and diagnostics development.
- Mathys & Squire, a top-tier intellectual property law firm that supports biotech innovation through patent strategy, IP protection, and legal expertise for life science companies
- Discovery Park, one of the UK’s premier science and innovation campuses, which provides flexible R&D facilities and fosters strategic partnerships for emerging biotech ventures.
- Ellab, a life science compliance partner helping biotech and pharma companies maintain product quality throughout manufacturing and storage by providing validation, monitoring, and calibration solutions.
The full list of exhibitors can be found here.
BioPharmaTrend is an official media partner for LBS 2025 and invites readers to secure a free visitor pass via the LBS 2025 official website, ensuring access to the exhibition. Stay tuned for the upcoming post-event coverage.
Topics: Bioeconomy & Society
